Inhaled Nitric Oxide Delivery System Market Will Expected to Reach More Than US$ 497.4 Million with a 5.4% CAGR by 2031 | TMR Insights

The global inhaled nitric oxide (iNO) delivery system market, valued at US$299.0 million in 2021, is anticipated to experience steady growth over the next decade. It is projected to grow at a compound annual growth rate (CAGR) of 5.4% from 2022 to 2031, surpassing US$497.4 million by the end of 2031. This consistent expansion reflects the increasing adoption of iNO therapy for pulmonary conditions, driven by rising neonatal care needs, chronic respiratory diseases, and advancements in delivery technology. As healthcare systems prioritize precise respiratory interventions, the market is poised for significant growth, reinforcing its critical role in critical care through 2031.

Get Sample PDF Brochure from here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85332

Understanding the Inhaled Nitric Oxide Delivery System Market
Inhaled nitric oxide is a selective pulmonary vasodilator administered via specialized delivery systems to treat conditions like persistent pulmonary hypertension of the newborn (PPHN), acute respiratory distress syndrome (ARDS), and pulmonary hypertension in adults. These systems include gas cylinders, regulators, and ventilatory integration devices ensuring precise dosing. The 2021 valuation of US$299.0 million underscores its established importance, with the projected rise to over US$497.4 million by 2031 highlighting its growing response to respiratory health challenges.

The 5.4% CAGR signals a stable yet dynamic growth phase, balancing established applications with emerging uses. iNO's role in improving oxygenation drives sustained market momentum.

Key Drivers of Market Growth

Several factors are propelling the iNO delivery system market toward its US$497.4 million milestone by 2031. First, the rising incidence of neonatal respiratory conditions is a primary driver. PPHN affects approximately 1-2 per 1,000 live births globally, per NIH estimates, with iNO as a standard therapy to reduce mortality and ventilator dependency. This neonatal demand aligns with the market's 5.4% CAGR, as advanced delivery systems enhance treatment outcomes.

Second, the growing prevalence of chronic lung diseases is accelerating growth. Conditions like chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH)-affecting over 300 million and 50 million people worldwide, respectively-benefit from iNO's vasodilatory effects. The COVID-19 pandemic further highlighted iNO's utility in ARDS management, driving the market toward US$497.4 million as respiratory care expands.

Third, technological advancements and regulatory support are boosting the market. Modern delivery systems-like those from Mallinckrodt or VERO Biotech-offer improved portability, safety (e.g., NO2 monitoring), and integration with ventilators. FDA approvals and CE markings for devices like the INOmax system support adoption, reinforcing the market's trajectory through 2031 as innovation meets clinical needs.

Leading Players:

Mallinckrodt
Santair AE
VERO Biotech
Linde plc
Beyond Air, Inc.
SLE
Bellerophon Therapeutics
Air Liquide Healthcare
International Biomedical
Circassia Pharmaceuticals

Visit our report to discover essential insights and analysis - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85332

Market Segmentation and Regional Insights

The market segments by application, end-user, and geography. Neonatal applications (e.g., PPHN) dominate due to established efficacy, followed by adult uses in PAH and ARDS. End-users include hospitals, neonatal intensive care units (NICUs), and ambulatory centers, with NICUs leading due to critical care demand. Distribution occurs via direct sales and medical equipment suppliers.

Regionally, North America held a significant share of the US$299.0 million valuation in 2021, driven by high preterm birth rates, advanced NICUs, and strong adoption in the United States. Europe followed, with robust markets in Germany and France, supported by healthcare infrastructure. The Asia-Pacific region, however, is expected to see the fastest growth through 2031, fueled by rising respiratory diseases, healthcare investments, and neonatal care improvements in China and India.

Challenges and Opportunities

The market faces challenges. High costs-iNO therapy can exceed thousands per day-limit accessibility, particularly in low-resource settings, while stringent regulatory requirements for gas purity and delivery systems delay launches. Limited awareness among general practitioners and competition from alternative vasodilators (e.g., sildenafil) also hinder growth. The 5.4% CAGR reflects a market navigating these constraints with steady progress.

These challenges, however, present opportunities. Companies developing cost-effective, portable systems-like VERO's GENOSYL-could broaden access, supporting the push to US$497.4 million. Innovations in outpatient delivery for chronic PAH or telemedicine integration offer growth potential, while expanding NICU networks in emerging markets could exceed projections. Partnerships with insurers to offset costs could further enhance uptake.

The Road to 2031

By 2031, the global iNO delivery system market is projected to surpass US$497.4 million, reflecting ten years of steady growth at a 5.4% CAGR from US$299.0 million in 2021. This milestone is driven by neonatal and respiratory needs, technological advancements, and healthcare priorities. As the forecast concludes, the market's trajectory suggests continued expansion, with potential for broader therapeutic applications to shape future growth.

In conclusion, the iNO delivery system market demonstrates solid growth from 2022 to 2031. Rising from US$299.0 million to over US$497.4 million, it addresses critical respiratory challenges with impactful solutions. Stakeholders-from device manufacturers to clinicians-play a vital role in this success, ensuring effective, accessible systems improve patient outcomes worldwide through 2031 and beyond.

Explore Latest Research Reports by Transparency Market Research:

Healthcare Biometrics Market: https://www.pharmiweb.com/press-release/2025-03-12/healthcare-biometrics-market-to-surpass-us-7408-billion-by-2035-driven-by-advancements-in-security-digital-health-solutions-tmr-insights

Healthcare Contract Research Outsourcing Market: https://www.pharmiweb.com/press-release/2025-03-12/healthcare-contract-research-outsourcing-market-to-surpass-us-6309-billion-by-2035-driven-by-increasing-demand-for-cost-effective-drug-development

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.